A phase II, multicentre trial of decitabine in higher-risk chronic myelomonocytic leukemia

Chronic myelomonocytic leukemia (CMML) is a complex clonal hematological disorder classified among myelodysplastic (MDS)/myeloproliferative neoplasms. Prognosis is poor and there is a lack of effective treatments. The hypomethylating agent decitabine has shown activity against MDS and elderly acute...

全面介紹

Na minha lista:
書目詳細資料
發表在:Leukemia
Main Authors: Santini, V, Allione, B, Zini, G, Gioia, D, Lunghi, M, Poloni, A, Cilloni, D, Sanna, A, Masiera, E, Ceccarelli, M, Abdel-Wahab, O, Terenzi, A, Angelucci, E, Finelli, C, Onida, F, Pelizzari, A, Ferrero, D, Saglio, G, Figueroa, M, Levis, A
格式: Artigo
語言:Inglês
出版: Nature Publishing Group 2018
主題:
Original Article
在線閱讀:https://ncbi.nlm.nih.gov/pmc/articles/PMC5808077/
https://ncbi.nlm.nih.gov/pubmed/28607470
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/leu.2017.186
標簽: 添加標簽
沒有標簽, 成為第一個標記此記錄!

相似書籍